All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-EGP-2 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human EGP-2. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGP-2 antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of Colorectal cancer.
CAR Construction : Fig.1 Mapping of the binding domain of adecatumumab to exon 5 of human EpCAM. FACS histograms showing the binding of adecatumumab to 293 cells expressing the EpCAM constructs shown in b. The bold line shows binding of detection antibodies in the presence of adecatumumab, the faint line binding in the absence of the mAb. Münz, M., Murr, A., Kvesic, M., Rau, D., Mangold, S., Pflanz, S., ... & Raum, T. (2010). Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer cell international, 10(1), 1-12. |
CAR Construction : Fig.2 ADCC activity of five clinically tested anti-EpCAM monoclonal antibodies. Cell lysis was determined by TDA released from lysed cells chelated with Europium and quantified by the fluorescence of the Europium-TDA chelates formed. Münz, M., Murr, A., Kvesic, M., Rau, D., Mangold, S., Pflanz, S., ... & Raum, T. (2010). Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer cell international, 10(1), 1-12. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-EGP-2 (SPM528) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-ZP3724). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION